Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?

imageGilda Varricchi1,2imageGianenrico Senna3imageStefania Loffredo1,2imageDiego Bagnasco4imageMatteo Ferrando4 and imageGiorgio Walter Canonica5*
1Division of Clinical Immunology and Allergy, Department of Translational Medical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy
2Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
3Asthma Center and Allergy Unit, Verona University, General Hospital, Verona, Italy
4Allergy and Respiratory Diseases, DIMI Department of Internal Medicine, IRCCS AOU San Martino-IST, University of Genova, Genova, Italy
5Personalized Medicine Clinic Asthma and Allergy Humanitas Clinical and Research Center, Department of Biomedical Science, Humanitas University, Rozzano, Milano, Italy

Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic inflammatory disorder that affects more than 315 million people worldwide, with 10% having severe uncontrolled disease. Although the majority of patients can be efficiently treated, severe asthmatics continue to be uncontrolled and are at risk of exacerbations and even death. Interleukin-5 (IL-5) plays a fundamental role in eosinophil differentiation, maturation, activation and inhibition of apoptosis. Therefore, targeting IL-5 is an appealing approach to the treatment of patients with severe eosinophilic asthma. Reslizumab, a humanized anti-IL-5 monoclonal antibody, binds with high affinity to amino acids 89–92 of IL-5 that are critical for binding to IL-5 receptor α. Two phase III studies have demonstrated that reslizumab administration in adult patients with severe asthma and eosinophilia (≥400 cells/μL) improved lung function, asthma control, and symptoms. Thus, the use of blood eosinophils as a baseline biomarker could help to select patients with severe uncontrolled asthma who are likely to achieve benefits in asthma control with reslizumab. In conclusion, targeted therapy with reslizumab represents one step closer to precision medicine in patients with severe eosinophilic asthma.


Download Article
 

 
 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Sarah B D on Twitter: "@picardonhealth I got the flu shot because I’… https://t.co/PKYRRO1cxM, see more https://t.co/CpGiFuOOYd
54mreplyretweetfavorite
Interasma Top story: Rae Brager on Twitter: "@DrAnneEllis Also decrease REM sleep and the… https://t.co/fy2uqXrC3v, see more https://t.co/CpGiFuOOYd
3hreplyretweetfavorite
Interasma Top story: Dr. Ellis on Twitter: "Rupatadine also low/moderate potential for in… https://t.co/RZVJTybrxF, see more https://t.co/CpGiFuOOYd
11hreplyretweetfavorite
Interasma Top story: Dr. Winder Gill on Twitter: "I'd like to do a poll of how many medic… https://t.co/DCyPZUyIAr, see more https://t.co/CpGiFuOOYd
13hreplyretweetfavorite
Interasma Top story: Salt raises blood pressure, but our gut bacteria can stop it https://t.co/4l5nkVGpC6, see more https://t.co/CpGiFuOOYd
14hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma